The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound ... causing pauses in breathing during sleep,” per the FDA. “Today’s approval marks the first drug treatment option for ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The the US Food and Drug Administration (FDA) has approved the first medication ... “Zepbound promotes weight loss and has been shown to reduce apnea events,” Troxel noted.

The FDA first approved Zepbound to treat obesity in November ... to treat Type 2 diabetes and became popular as an off-label weight-loss treatment. Tirzepatide works by stimulating two hormones ...